Trial · NCT03726268

Optimizing Outpatient Anesthesia (OSPREy-Outpatient Surgery Pain Relief Enhancement)

NCT03726268, Phase 4, Completed, Duke University; results first posted 2025-11-19

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Optimizing Outpatient Anesthesia (OSPREy-Outpatient Surgery Pain Relief Enhancement). Trials, record NCT03726268. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03726268

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Optimizing Outpatient Anesthesia (OSPREy-Outpatient Surgery Pain Relief Enhancement)
NCT number: NCT03726268
Status: Completed
Phases: Phase 4
Enrollment: 907 participants, actual
Lead sponsor: Duke University
Conditions: Opioid Use, Pain, Postoperative
Interventions: Methadone, Fentanyl, Hydromorphone, Morphine, Sufentanil
First posted: 2018-10-31
Last updated: 2025-11-19
Results first posted: 2025-11-19

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Total 30 Day Post-discharge Home Opioid Use (Number of Tablets)	Approximately 30 days	Based on home diary and hospital record. Number of opioid tablets from PACU discharge to postoperative day (POD) 30 for Same Day subjects, and number of opioid tablets from POD 1 to POD 30 for Short-Stay subjects.
Secondary	Total Intraoperative Non-methadone Opioid Administration	Approximately 12 hours	Based on hospital record.
Secondary	Total Post Anesthesia Care Unit (PACU) Opioid Administration	Approximately 2 hours	Based on hospital record.
Secondary	Total Hospital Non-methadone Opioid Administration	Start of surgery to hospital discharge, up to 2 days	Based on hospital record.
Secondary	Total 7-day Post-PACU Discharge Home Opioid Use	Up to 7 days post-PACU discharge	Based on home diary and hospital record. Number of opioid tablets from PACU discharge to postoperative day (POD) 7 for Same Day subjects, and number of opioid tablets from POD 1 to POD 7 for Short-Stay subjects.

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Total 30 Day Post-discharge Home Opioid Use (Number of Tablets)	Approximately 30 days		tablets	MEAN
SECONDARY	Total Intraoperative Non-methadone Opioid Administration	Approximately 12 hours		Milligram Morphine Equivalent (MME)	MEDIAN
SECONDARY	Total Post Anesthesia Care Unit (PACU) Opioid Administration	Approximately 2 hours		Milligram Morphine Equivalent (MME)	MEDIAN
SECONDARY	Total Hospital Non-methadone Opioid Administration	Start of surgery to hospital discharge, up to 2 days		Milligram Morphine Equivalent (MME)	MEDIAN
SECONDARY	Total 7-day Post-PACU Discharge Home Opioid Use	Up to 7 days post-PACU discharge	Participants with data collected.	tablets	MEAN

Source ClinicalTrials.gov

Results by group20

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Total 30 Day Post-discharge Home Opioid Use (Number of Tablets)	Short-stay, IV Methadone	10.00	Standard Deviation 15.50	tablets
Total 30 Day Post-discharge Home Opioid Use (Number of Tablets)	Short-stay, IV Short-acting Opioids	10.00	Standard Deviation 11.60	tablets
Total 30 Day Post-discharge Home Opioid Use (Number of Tablets)	Same-day, IV Methadone	6.18	Standard Deviation 8.40	tablets
Total 30 Day Post-discharge Home Opioid Use (Number of Tablets)	Same-day, IV Short-acting Opioids	6.67	Standard Deviation 10.40	tablets
Total Intraoperative Non-methadone Opioid Administration	Short-stay, IV Methadone	0.0	Inter-Quartile Range 0.0 to 0.0	Milligram Morphine Equivalent (MME)
Total Intraoperative Non-methadone Opioid Administration	Short-stay, IV Short-acting Opioids	18.0	Inter-Quartile Range 14.0 to 23.0	Milligram Morphine Equivalent (MME)
Total Intraoperative Non-methadone Opioid Administration	Same-day, IV Methadone	0.0	Inter-Quartile Range 0.0 to 0.0	Milligram Morphine Equivalent (MME)
Total Intraoperative Non-methadone Opioid Administration	Same-day, IV Short-acting Opioids	16.7	Inter-Quartile Range 12.7 to 24.0	Milligram Morphine Equivalent (MME)
Total Post Anesthesia Care Unit (PACU) Opioid Administration	Short-stay, IV Methadone	2.0	Inter-Quartile Range 0 to 4.0	Milligram Morphine Equivalent (MME)
Total Post Anesthesia Care Unit (PACU) Opioid Administration	Short-stay, IV Short-acting Opioids	3.0	Inter-Quartile Range 0.0 to 7.0	Milligram Morphine Equivalent (MME)

1 to 10 of 20Source ClinicalTrials.gov

See all 20 results by group

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Short-stay, IV Methadone	188
Overall Study	STARTED	Short-stay, IV Short-acting Opioids	188
Overall Study	STARTED	Same-day, IV Methadone	205
Overall Study	STARTED	Same-day, IV Short-acting Opioids	205
Overall Study	COMPLETED	Short-stay, IV Methadone	175
Overall Study	COMPLETED	Short-stay, IV Short-acting Opioids	175
Overall Study	COMPLETED	Same-day, IV Methadone	190
Overall Study	COMPLETED	Same-day, IV Short-acting Opioids	194
Overall Study	NOT COMPLETED	Short-stay, IV Methadone	13
Overall Study	NOT COMPLETED	Short-stay, IV Short-acting Opioids	13

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events356

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	COVID	Respiratory, thoracic and mediastinal disorders	Short-stay, IV Methadone	1	188
other	COVID	Respiratory, thoracic and mediastinal disorders	Short-stay, IV Short-acting Opioids	0	188
other	COVID	Respiratory, thoracic and mediastinal disorders	Same-day, IV Methadone	1	205
other	COVID	Respiratory, thoracic and mediastinal disorders	Same-day, IV Short-acting Opioids	2	205
other	DVT	Vascular disorders	Short-stay, IV Methadone	1	188
other	DVT	Vascular disorders	Short-stay, IV Short-acting Opioids	1	188
other	DVT	Vascular disorders	Same-day, IV Methadone	1	205
other	DVT	Vascular disorders	Same-day, IV Short-acting Opioids	0	205
other	abdominal distension	Gastrointestinal disorders	Short-stay, IV Methadone	0	188
other	abdominal distension	Gastrointestinal disorders	Short-stay, IV Short-acting Opioids	2	188

1 to 10 of 356Source ClinicalTrials.gov

See all 356 adverse events

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Short-stay, IV Methadone	0	188
Total, all-cause mortality	Short-stay, IV Short-acting Opioids	1	188
Total, all-cause mortality	Same-day, IV Methadone	0	205
Total, all-cause mortality	Same-day, IV Short-acting Opioids	0	205
Total, other adverse events	Short-stay, IV Methadone	21	188
Total, other adverse events	Short-stay, IV Short-acting Opioids	17	188
Total, other adverse events	Same-day, IV Methadone	29	205
Total, other adverse events	Same-day, IV Short-acting Opioids	16	205
Total, serious adverse events	Short-stay, IV Methadone	6	188
Total, serious adverse events	Short-stay, IV Short-acting Opioids	6	188

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
38447097	DERIVED

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R01DA042985	OPTIMIZING OUTPATIENT ANESTHESIA: IMPROVING ANALGESIA AND REDUCING OPIOID MISADVENTURE	KHARASCH, EVAN D.	DUKE UNIVERSITY	NATIONAL INSTITUTE ON DRUG ABUSE	2017 to 2021

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03726268

GET https://conductscience.org/api/trials/v1/NCT03726268/events?page=2

API reference For AI assistants